Drugs / Rilmenidine
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02539810 | Sep 2015 → Dec 2016 | renal artery atheroma, resistant hypertension | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 4 | NCT00892892 | Nov 2009 → Jun 2011 | chronic kidney disease, hypertensive disorder | University of Erlangen-Nürnberg Medical School | Withdrawn | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rilmenidine | “rilmenidine 1 mg/d” NCT02539810 ↗ |
| Known as | Hyperium | ChEMBL registry synonym — accepted as the source's own label CHEMBL289480 ↗ |
| Known as | Rilmenidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL289480 ↗ |
| Known as | RILMENIDINE HEMIFUMARATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL289480 ↗ |
| Action | Activate | “Nischarin agonist” CHEMBL289480 ↗ |
| Modality | Small molecule | — CHEMBL289480 ↗ |
| Target | NISCH | “Nischarin agonist” CHEMBL289480 ↗ |